Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shot for hemophilia a: could marstacimab be a Game-Changer?

NCT ID NCT06703606

First seen Apr 03, 2026 · Last updated May 21, 2026 · Updated 9 times

Summary

This study tests a new medicine called marstacimab for people with severe hemophilia A who want to switch from their current treatment (emicizumab). Hemophilia A is a rare bleeding disorder where blood doesn't clot properly. The study will check if marstacimab is safe and how it works in the body. Participants will receive weekly injections for 4 months, and the study lasts up to 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE HEMOPHILIA A are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ege University Faculty of Medicine Dean's Office

    RECRUITING

    Bornova, İzmir, 35100, Turkey (Türkiye)

  • K J Somaiya Hospital & Research Centre

    RECRUITING

    Mumbai, Maharashtra, 400022, India

  • Nirmal Hospital Pvt Ltd.

    RECRUITING

    Surat, Gujarat, 395002, India

  • Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center

    RECRUITING

    Los Angeles, California, 90007, United States

Conditions

Explore the condition pages connected to this study.